Roche’s Avastin plus chemotherapy receives FDA approval to treat cervical cancer
Switzerland-based Roche has received approval from the US Food and Drug Administration (FDA) for its Avastin (bevacizumab), in combination with paclitaxel and cisplatin or paclitaxel and topotecan, to treat women with persistent, recurrent or metasta…
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news
More News: Avastin | Cancer | Cancer & Oncology | Cervical Cancer | Chemotherapy | Food and Drug Administration (FDA) | Pharmaceuticals | Women